New Insights into the Role of Metformin Effects on Serum Omentin-1 Levels in Acute Myocardial Infarction: Cross-Sectional Study
Table 4
Biochemical changes and serum omentin-1 level in acute MI in the patients that were not previously treated with metformin prior to acute MI in comparison with the patients previously treated with metformin.
Biochemical parameters
Group I () Mean ± SD
Group II () Mean ± SD
95% CI Upper-lower limits
p
S. omentin-1 pg/mL
25.43 ± 1.2
23.71 ± 1.161
11.2861
25.7347–25.1253
<0.0001
S. troponin-I pg/mL
75.453 ± 5.62
79.53 ± 3.60
−5.7122
76.8802–74.0258
<0.0001
FBG mg/dL
137.75 ± 13.139
138.77 ± 17.467
−0.6113
141.0867–134.4133
0.5433
Total cholesterol mg/dL
152.63 ± 16.877
242.44 ± 12.552
−41.9011
156.916–148.344
<0.0001
TG mg/dL
149.34 ± 23.31
246.55 ± 57.607
−32.8371
155.2596–143.4204
<0.0001
HDL-C mg/dL
54.24 ± 8.355
38.77 ± 4.570
14.5794
56.3618–52.1182
<0.0001
VLDL-C mg/dL
29.86 ± 4.662
49.30 ± 11.524
−32.8337
31.0439–28.6761
<0.0001
LDL-C mg/dL
68.13 ± 3.937
154.37 ± 4.316
−13581.08
68.1427–68.1173
<0.0001
AI
0.082 ± 0.09
0.443 ± 0.084
−31.5835
0.1049–0.0591
<0.0001
SPB mmHg
140.33 ± 8.773
162.33 ± 10.61
−19.745
142.5579–138.1021
<0.0001
DPB mmHg
82.16 ± 8.773
105.16 ± 21.784
−20.6431
84.3879–79.9321
<0.0001
Group I: patients received metformin prior to acute MI. Group II: patients have not received metformin prior to acute MI. . FBG: fasting blood glucose, TG: triglyceride, HDL: high density lipoprotein, VLDL: very low density lipoprotein, LDL: low density lipoprotein, AI: atherogenic index, SPB: systolic blood pressure, and DPB: diastolic blood pressure.
